Vaspin and its relation to cancer (Review)

Agarwal,Shubham; Desai,Shreya

doi:10.3892/wasj.2021.129

Vaspin and its relation to cancer (Review)

Authors:
- Shubham Agarwal
- Shreya Desai
View Affiliations

Affiliations: Division of Internal Medicine, Chicago Medical School at Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA
Published online on: September 23, 2021 https://doi.org/10.3892/wasj.2021.129
Article Number: 58
Copyright: © Agarwal et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adipose tissue releases signaling molecules and hormones which are known as adipokines. Adipose tissue also provides a medium for low‑grade inflammation which occurs from adipocyte hypertrophy with ensuing hypoxia and cell death. Cancers are known to arise in states of low‑grade inflammation. There have been attempts to understand the role of adipokines in cancer pathogenesis and to establish their use as diagnostic and prognostic tools, as well as treatment targets. The present review article aims to highlight the role of vaspin in various types of cancer. Vaspin is known to inhibit apoptosis via the phosphatidylinositol‑3‑kinase/protein kinase B pathway, which has also been implicated in the development of colorectal cancer. The inhibition of the apoptosis of cells with malignant potential promotes tumor formation. At the same time, vaspin exhibits anti‑inflammatory and insulin‑sensitizing properties, which possibly confer its tumor inhibitory effects observed in endometrial cancer. However, its role either as a tumor promoter or inhibitor in other types of cancer in which it has not yet been studied would be difficult to predict.

View Figures

View References

1	Booth A, Magnuson A, Fouts J and Foster M: Adipose tissue, obesity and adipokines: Role in cancer promotion. Horm Mol Biol Clin Investig. 21:57–74. 2015.PubMed/NCBI View Article : Google Scholar
2	Iyengar NM, Gucalp A, Dannenberg AJ and Hudis CA: Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J Clin Oncol. 34:4270–4276. 2016.PubMed/NCBI View Article : Google Scholar
3	Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 348:1625–1638. 2003.PubMed/NCBI View Article : Google Scholar
4	Fuster JJ, Ouchi N, Gokce N and Walsh K: Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res. 118:1786–1807. 2016.PubMed/NCBI View Article : Google Scholar
5	Cotillard A, Poitou C, Torcivia A, Bouillot JL, Dietrich A, Klöting N, Grégoire C, Lolmede K, Blüher M and Clément K: Adipocyte size threshold matters: Link with risk of type 2 diabetes and improved insulin resistance after gastric bypass. J Clin Endocrinol Metab. 99:E1466–E1470. 2014.PubMed/NCBI View Article : Google Scholar
6	Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, et al: Visceral adipose tissue-derived serine protease inhibitor: A unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA. 102:10610–10615. 2005.PubMed/NCBI View Article : Google Scholar
7	Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL and Park JY: Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 413:264–269. 2011.PubMed/NCBI View Article : Google Scholar
8	Fazeli MS, Dashti H, Akbarzadeh S, Assadi M, Aminian A, Keramati MR and Nabipour I: Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine. 62:81–85. 2013.PubMed/NCBI View Article : Google Scholar
9	Erdogan S, Yilmaz FM, Yazici O, Yozgat A, Sezer S, Ozdemir N, Uysal S, Purnak T, Sendur MA and Ozaslan E: Inflammation and chemerin in colorectal cancer. Tumour Biol. 37:6337–6342. 2016.PubMed/NCBI View Article : Google Scholar
10	Kan JY, Lee YC, Lin YD, Ho WY and Moi SH: Effect of baseline characteristics and tumor burden on vaspin expression and progressive disease in operable colorectal cancer. Diagnostics (Basel). 10(801)2020.PubMed/NCBI View Article : Google Scholar
11	Wong RS: Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 30(87)2011.PubMed/NCBI View Article : Google Scholar
12	Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 1855:104–121. 2015.PubMed/NCBI View Article : Google Scholar
13	Kukla M, Mazur W, Bułdak RJ and Zwirska-Korczala K: Potential role of leptin, adiponectin and three novel adipokines - visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med. 17:1397–1410. 2011.PubMed/NCBI View Article : Google Scholar
14	Kukla M, Waluga M, Sawczyn T, Berdowska A, Kajor M, Boryczka G, Stygar D, Gabriel A, Zwirska-Korczala K and Hartleb M: Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy. Pol J Pathol. 63:213–220. 2012.PubMed/NCBI View Article : Google Scholar
15	Pazgan-Simon M, Kukla M, Zuwała-Jagiełło J, Derra A, Bator M, Menżyk T, Lekstan A, Grzebyk E and Simon K: Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC). PLoS One. 15(e0227459)2020.PubMed/NCBI View Article : Google Scholar
16	Skonieczna M, Hudy D, Hejmo T, Buldak RJ, Adamiec M and Kukla M: The adipokine vaspin reduces apoptosis in human hepatocellular carcinoma (Hep-3B) cells, associated with lower levels of NO and superoxide anion. BMC Pharmacol Toxicol. 20(58)2019.PubMed/NCBI View Article : Google Scholar
17	Cymbaluk-Płoska A, Chudecka-Głaz A, Jagodzinska A, Pius-Sadowska E, Sompolska-Rzechuła A, Machaliński B and Menkiszak J: Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer. Onco Targets Ther. 11:1363–1372. 2018.PubMed/NCBI View Article : Google Scholar
18	Erdogan S, Sezer S, Baser E, Gun-Eryilmaz O, Gungor T, Uysal S and Yilmaz FM: Evaluating vaspin and adiponectin in postmenopausal women with endometrial cancer. Endocr Relat Cancer. 20:669–675. 2013.PubMed/NCBI View Article : Google Scholar
19	Phalitakul S, Okada M, Hara Y and Yamawaki H: Vaspin prevents TNF-α-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-κB and PKCθ activation in cultured rat vascular smooth muscle cells. Pharmacol Res. 64:493–500. 2011.PubMed/NCBI View Article : Google Scholar
20	Jabbari S, Hedayati M, Yaghmaei P and Parivar K: Medullary thyroid carcinoma - Circulating status of vaspin and retinol binding protein-4 in Iranian patients. Asian Pac J Cancer Prev. 16:6507–6512. 2015.PubMed/NCBI View Article : Google Scholar
21	Ginis Z, Ucar F, Erdogan S, Ozturk G, Akyol S, Erden G, Arslan MS and Delibasi T: Serum vaspin and adiponectin levels in patients with prolactinoma. Scand J Clin Lab Invest. 76:17–24. 2016.PubMed/NCBI View Article : Google Scholar
22	Zhu X, Jiang Y, Shan PF, Shen J, Liang QH, Cui RR, Liu Y, Liu GY, Wu SS, Lu Q, et al: Vaspin attenuates the apoptosis of human osteoblasts through ERK signaling pathway. Amino Acids. 44:961–968. 2013.PubMed/NCBI View Article : Google Scholar